Point Substitution in the Central Hydrophobic Cluster of a Human β-Amyloid Congener Disrupts Peptide Folding and Abolishes Plaque Competence

Alzheimer's disease (AD) is pathologically characterized by the presence of numerous insoluble amyloid plaques in the brain composed primarily of a 40−43 amino acid peptide, the human β-amyloid peptide (Aβ). The process of Aβ deposition can be modeled in vitro by deposition of physiological con...

Full description

Saved in:
Bibliographic Details
Published inBiochemistry (Easton) Vol. 35; no. 44; pp. 13914 - 13921
Main Authors Esler, William P, Stimson, Evelyn R, Ghilardi, Joseph R, Lu, Yi-An, Felix, Arthur M, Vinters, Harry V, Mantyh, Patrick W, Lee, Jonathan P, Maggio, John E
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 05.11.1996
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Alzheimer's disease (AD) is pathologically characterized by the presence of numerous insoluble amyloid plaques in the brain composed primarily of a 40−43 amino acid peptide, the human β-amyloid peptide (Aβ). The process of Aβ deposition can be modeled in vitro by deposition of physiological concentrations of radiolabeled Aβ onto preexisting amyloid in preparations of unfixed AD cerebral cortex. Using this model system, it has been shown that Aβ deposition is biochemically distinct from Aβ aggregation and occurs readily at physiological Aβ concentrations, but which regions and conformations of Aβ are essential to Aβ deposition is poorly understood. We report here that an active congener, Aβ(10−35)-NH2, displays time dependence, pH−activity profile, and kinetic order of deposition similar to Aβ(1−40), and is sufficiently soluble for NMR spectroscopy in water under conditions where it actively deposits. To examine the importance of the central hydrophobic cluster of Aβ (LVFFA, residues 17−21) for in vitro Aβ deposition, an Aβ(10−35)-NH2 analog with a single point substitution (F19T) in this region was synthesized and examined. Unlike Aβ(10−35)-NH2, the F19T analog was plaque growth incompetent, and NMR analysis indicated that the mutant peptide was significantly less folded than wild-type Aβ. These results support previous studies suggesting that the plaque competence of Aβ correlates with peptide folding. Since compounds that alter Aβ folding may reduce amyloid deposition, the central hydrophobic cluster of Aβ will be a tempting target for structure-based drug design when high-resolution structural information becomes available.
Bibliography:ark:/67375/TPS-1D732PL7-H
Abstract published in Advance ACS Abstracts, September 15, 1996.
istex:340A82F344D659A8B613694E318FDFA943A8B106
This work was supported by grants from the National Institutes of Health (AG-12853, AG-10123, AG-12435, and AG-11852), the American Health Assistance Foundation (94071), and the Veterans' Administration (Merit Review).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-2960
1520-4995
DOI:10.1021/bi961302+